ART Advanced Research Technologies to protected $1.2M interim financing ART Advanced Research Systems Inc www.montfordpharmacy.com . , a Canadian medical device business and a innovator in optical molecular imaging items for the health care and pharmaceutical sectors, announced that earlier today it filed a notice of intention to make a proposal to its lenders under the Bankruptcy and Insolvency Act with KPMG Inc. In order to provide the organization with the liquidity it requires to go after its solicitation process.
Individuals, physicians and other health care professionals seeking additional information regarding trials concerning ARQ 197 may contact 1-800-373-7827. The American Tumor Society’s estimates of the effect of lung malignancy in the U.S. During 2009 include 219 approximately,000 new situations and 159,000 deaths resulting from the disease, accounting for 28 % of all cancer deaths. Lung cancers is the leading reason behind cancer death among both men and women.. ARQ 197 demonstrates 66 percent improvement in median PFS in sufferers with advanced NSCLC ArQule, Inc. today announced that ARQ 197, when found in combination with erlotinib, demonstrated a 66 percent improvement in median Progression-Free Survival in sufferers with advanced, refractory non-small cell lung cancers .